-
-
-
-
-
-
-
TransCode licenses cancer immunotherapy platform in stock deal
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Issues Letter to Shareholders
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Announces Proposed Share Offering
-
482,474 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


